Barrington Research Maintains DENTSPLY $45 PT, Outperform
Barrington Research maintained its DENTSPLY (NASDAQ: XRAY) $45 price target and Outperform rating in a research report published today.
In the report, Barrington Research states, "Management initiated fiscal 2012 guidance to a range of $2.22-2.30 per diluted share on adjusted basis. Currency exchange rates are expected to have a negative impact in 2012 on both top and bottom lines. The company cited innovation, a key driver of its results in 2011 and noted that there were several exciting new products in the pipeline."
Shares of DENTSPLY closed today at $38.74, down 0.79% from Friday's market close.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.